We use our own and third-party cookies to optimize your experience on this site, including to maintain user sessions. Without these cookies our site will not function well. If you continue browsing our site we take that to mean that you understand and accept how we use the cookies. If you wish to decline our cookies we will redirect you to Google.
Already have an account? Sign in.

 Remember Me | Forgot Your Password?

Weight Loss Drug Shows Potential In Fight Against Opiate Addiction

March 31, 2017: 12:00 AM EST
In an animal study, a prescription weight-loss drug was shown to reduce the craving for the opioid oxycodone, according to U.S. researchers.  Opiate abuse is a major public health problem: deaths from prescription opiate overdose in America have quadrupled since 1999.The preclinical study offers a ray of hope, finding that lorcaserin (trade name Belviq, Arena Pharmaceuticals) alters the serotonin system by changing chemical signals that affect the feeling of fullness. It works much the same way with opiates, as serotonin regulates the brain circuitry involved in drug reward. The researchers said the effectiveness of lorcaserin in reducing oxycodone cravings underscores the potential for lorcaserin in treating opioid use disorder.
Harshini Neelakantan et al., "Lorcaserin Suppresses Oxycodone Self-Administration and Relapse Vulnerability in Rats", ACS Chemical Neuroscience, March 31, 2017, © American Chemical Society
Other Conditions
North America
United States of America
Research, Studies, Advice
Developed by Yuri Ingultsov Software Lab.